59.35
Schlusskurs vom Vortag:
$59.77
Offen:
$57.5
24-Stunden-Volumen:
2.04M
Relative Volume:
1.49
Marktkapitalisierung:
$7.33B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
19.65
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-6.99%
1M Leistung:
-2.67%
6M Leistung:
+10.21%
1J Leistung:
+44.51%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Vergleichen Sie HALO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
59.35 | 7.33B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
2024-02-29 | Eingeleitet | TD Cowen | Outperform |
2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-03-27 | Fortgesetzt | Berenberg | Buy |
2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-01-21 | Bestätigt | The Benchmark Company | Buy |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2020-01-08 | Eingeleitet | Goldman | Buy |
2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
2018-01-24 | Eingeleitet | Goldman | Neutral |
2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
2015-11-18 | Eingeleitet | Citigroup | Buy |
2015-09-22 | Eingeleitet | Barclays | Overweight |
2015-06-22 | Bestätigt | JP Morgan | Overweight |
2015-03-03 | Bestätigt | UBS | Buy |
2015-02-18 | Bestätigt | MLV & Co | Buy |
2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
J&J, Halozyme win EU nod for injectable Rybrevant (JNJ:NYSE) - Seeking Alpha
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com Canada
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
Major EU Victory: Halozyme's ENHANZE Tech Gets Green Light for Advanced Lung Cancer - Stock Titan
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com India
4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - The Malaysian Reserve
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Zacks Research Issues Negative Outlook for HALO Earnings - Defense World
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance
Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN
Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN
Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada
High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance
JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight - Fierce Pharma
Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal
Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):